Drug Trial Radar · NCT05110807
A Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB3617 Capsule in Patients With Advanced Malignant Tumors
Last checked: Nov 19, 2026Latest source record: Feb 14, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
38
Planned (sponsor's estimate)
Start
Jan 5, 2022
Primary completion
Oct 2022
Study completion Dec 2022
Sponsor
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 8, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
TQB3617 is a bromodomain and extra-terminal (BET) inhibitor that can competitively bind to bromodomains (BRDs) with Acetylated lysine(Kac) and block or partially block the role of KAc in subsequent gene transcription and regulation of chromatin structure, thereby playing an anti-tumor role.
Conditions
- Advanced Malignant Tumors
Interventions
TQB3617Drug
TQB3617 is a BET inhibitor.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum tolerated dose (MTD)Time frame: Baseline up to 48 weeks
- Adverse events (AEs) and serious adverse events (SAEs)Time frame: Baseline up to 48 weeks
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Sun Yat-sen University Cancer Cen
Guangzhou, Guangdong, China · Recruiting
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.